Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy.
Yongpeng GeShanshan LiXiaolan TianLinrong HeXin LuGuochun WangPublished in: Clinical rheumatology (2021)
Our study found that RTX is sufficient to improve skin rash and ILD or RP-ILD. Our results also suggest that lower RTX doses may be a useful therapy for anti-MDA5 antibody-positive DM patients. Key Points • To clarify efficacy of RTX in the management of anti-MDA5 antibody-positive DM, we performed a retrospective chart review of DM patients with anti-MDA5 antibodies who were treated with RTX. • This study found that RTX is sufficient to improve skin rash and ILD or RP-ILD. • The results suggest that low-dose RTX in treatment of MDA5-DM results in better responses and fewer adverse events.
Keyphrases
- interstitial lung disease
- breast cancer cells
- systemic sclerosis
- low dose
- rheumatoid arthritis
- cell cycle arrest
- newly diagnosed
- end stage renal disease
- ejection fraction
- type diabetes
- glycemic control
- gene expression
- genome wide
- stem cells
- dna methylation
- cell death
- cell proliferation
- disease activity
- skeletal muscle
- peritoneal dialysis
- hodgkin lymphoma
- chronic lymphocytic leukemia